Monday November 23 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Uracil Nucleotides

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Recent Publications on Uracil Nucleotides:

Pubmed Logo
The P2Y-like receptor GPR17 as a sensor of damage and a new potential target in spinal cord injury.
Upon central nervous system injury, the extracellular concentrations of...
30th October, 2009
Laboratory of Molecular and Cellular Pharmacology of Purinergic Brain. 2009 Aug;132(Pt 8):2206-18. Epub 2009 Jun 15.
DOI Direct Link
Molecular recognition in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose.
The P2Y(14) receptor, a nucleotide signaling protein, is activated by...
9th October, 2009
Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Bioorg Med Chem. 2009 Jul 15;17(14):5298-311. Epub 2009 May 15.
DOI Direct Link
Inhibitor design for ribonuclease A: the binding of two 5'-phosphate uridine analogues.
In the quest for the rational design of selective and potent inhibitors...
6th October, 2009
Institute of Organic and Pharmaceutical Chemistry, National Hellenic Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009 Jul 1;65(Pt
DOI Direct Link
Functional characterization of two isoforms of the P2Y-like receptor GPR17: [35S]GTPgammaS binding and electrophysiological studies in 1321N1 cells.
The previously "orphan" G protein-coupled receptor GPR17 is structurally...
25th July, 2009
Department of Preclinical and Clinical Pharmacology, University of Am J Physiol Cell Physiol. 2009 Oct;297(4):C1028-40. Epub 2009 Jul 22.
DOI Direct Link
Structural basis of transcription: mismatch-specific fidelity mechanisms and paused RNA polymerase II with frayed RNA.
We show that RNA polymerase (Pol) II prevents erroneous transcription in...
25th July, 2009
Department of Chemistry and Biochemistry, Gene Center Munich and Center Mol Cell. 2009 Jun 26;34(6):710-21.
DOI Direct Link

View more research publications.

Press Releases About Uracil Nucleotides:

BioPortfolio Logo
Idenix Pharmaceuticals Presents Data on IDX184 for the Treatment of Hepatitis C Virus (HCV) 30th October, 2009 Idenix Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 30 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of

Uracil Nucleotides Patents:

USPTO Logo
US Patent No.Title
5789199 Process for bacterial production of polypeptides
6387645 Methods and materials relating to novel CD39-like polypeptides
6395478 Identification and comparison of protein-protein interactions that occur in populations and indentification of inhibitors of these interactors
6410239 Identification and comparison of protein--protein interactions that occur in populations and identification of inhibitors of these interactors
6426191 Assays involving an IL-1 receptor antagonist

View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Uracil Nucleotides scientists - we have details of around 503 individuals working on Uracil Nucleotides .


This page has been viewed 274 times
Recent Search Terms used to find this page: uracil nucleotides | .
Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Uracil Nucleotides across BioPortfolio, or for Uracil Nucleotides Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.